BANCO SANTANDER, S.A.
Last · —$12.13-0.048 (-0.39%)live · yahoo · 1h ago
Vol 23.55M ≈ 282.54M
MA10MA20MA50
Market cap$194.09B—
P/E · TTM13.6fwd — · eps —
Beta—vs S&P 500
Div yield—annual · TTM
52w range
——
Volume—session
Issuer
Legal nameBANCO SANTANDER, S.A.
HQUnited States (US)
ListingUS SAN
ISINES0113900J37
SectorHealthcare
IndustryBanks
SIC6029
CurrencyEUR
Entity registrylei:5493006QMFDDMYWIAM13
CIK0000891478
Websitewww.santander.com
Employees186,370
AddressBanco Santander SA Ciudad Grupo Santander 28660, Madrid +34 912 76 92 90
| Revenue | €3.7B |
|---|---|
| Net income | €14.1B |
| Free cash flow | €-20.7B |
| Net margin | 378.7% |
| Return on equity | 343.2% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
20-F · 2026-02-27
From latest 20-F · 2026-02-27
- Operating Cf Burn
- Cash Conversion Weak
Red flags
- Operating Cf Burn — Negative operating cash flow
- Cash Conversion Weak — Cash conversion (CFO/Rev) -398.4%
Upcoming earnings
WED.28OCT
4:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.24
Est. revenue
16.8B
Earnings transcripts
Press & signals
- GlobeNewswire
Press Release: Sanofi evolves its Executive Committee to support its next strategic chapter
- GlobeNewswire
Sanofi: Information concerning the total number of voting rights and shares - June 2026
- GlobeNewswire
Press Release: Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector
The rest of this company's wire — with summaries and source links — is part of Pro.
See plans